Equity Profile

OGN

Organon & Co.

Health CarePharmaceuticals$3.5B

Apr30Thu

Post-Earnings Recap

ReportedQ1-2026Pre-Market7:30 AM EDT

Organon & Co. Misses on EPS, Stock Down 0.67%

Metric	Actual	Expected	Surprise
EPS	$0.71	$0.85	-12.88%
Revenue	N/A	$1.5B	N/A

management commentary, guidance changes, and full analysis available with Pro.

Organon & Co. Misses on EPS, Stock Down 0.67%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.71	$0.85	-12.88%
Revenue	N/A	$1.5B	N/A

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

Organon & Co. reported lower-than-expected earnings per share, which likely contributed to the slight decline in stock price. Investors were anticipating a stronger performance, and the lack of revenue data adds uncertainty. Without guidance or management commentary, it remains unclear how the company plans to address these challenges moving forward.

Company Snapshot

Organon & Co. is a pharmaceutical company focused on women's health and other critical health issues....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability, and investors will be looking for a solid performance compared to expectations.

$0.85

Revenue

Revenue figures provide insight into the company's sales performance and overall market demand for its products.

$1.5B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Organon & Co. is a pharmaceutical company focused on women's health and other critical health issues. Operating in the health care sector, it plays a significant role in developing treatments that address unmet medical needs, making it an important player in the pharmaceutical industry.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+7.95%

Avg Stock Reaction

-3.38%

Last Quarter Recap

In Q4 2025, Organon reported an EPS of $0.63, missing expectations of $0.70, which led to an 8.19% drop in stock price the following day. The company did not provide revenue figures for that quarter.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Organon to report an EPS of $0.85 and revenue of $1.5 billion for Q1 2026, reflecting cautious optimism following recent earnings trends.

Bull Case

If Organon beats EPS expectations, it could signal a strong recovery and renewed investor confidence, potentially driving the stock higher.

Bear Case

A miss on EPS or revenue could raise concerns about the company's growth trajectory and lead to further declines in stock price.

Key Metrics to Watch

EPS

$0.85

Earnings per share is a key indicator of profitability, and investors will be looking for a solid performance compared to expectations.

Revenue

$1.5B

Revenue figures provide insight into the company's sales performance and overall market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Organon achieve an EPS of at least $0.85?

This figure is crucial for assessing the company's profitability and could significantly influence investor sentiment.

What revenue figures will Organon report, and how do they compare to the $1.5 billion consensus?

Revenue performance is key to understanding market demand and the company's growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for a strong recovery in EPS, given recent trends in women's health products that could drive sales.

Supporting Evidence

Organon has a history of beating EPS estimates, with an 88% success rate over the last eight quarters.

The options market is pricing a smaller move than historical averages, suggesting that investors may be overly cautious.

Recent trends in the pharmaceutical sector indicate increasing demand for women's health products, which could positively impact revenue.

Key Risk

If the company reports an EPS significantly above $0.85, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing recent earnings performance against expectations for growth, making this quarter critical for future outlook.

Bull Confirmed If

An EPS of $0.90 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.77 would indicate ongoing challenges and could lead to a negative market reaction.

Pre-Earnings Positioning

Options Market

Implied Move

±3.19%

Historical Avg

±10.8%

Pricing cheap

The options market is pricing a relatively modest move around the earnings report, suggesting that investors are uncertain about significant changes.

Options are pricing ±3.2% while OGN has averaged ±10.8% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.1%

30d HV

129.9%

Calls (4.1M)P/C Ratio: 0.05Puts (838K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Organon beats expectations, history suggests the stock could rise by around 2% on the first day, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may see minimal movement as investors assess management's commentary.

Miss

A miss could lead to a decline of about 8% based on historical patterns, raising concerns about the company's growth trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in women's health.
2Insights into market demand and sales trends for key products.
3Management's outlook on future growth and potential challenges.
4Details on cost management and operational efficiency improvements.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Gerdau S.A.

Company Snapshot

Organon & Co. is a pharmaceutical company focused on women's health and other critical health issues....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability, and investors will be looking for a solid performance compared to expectations.

$0.85

Revenue

Revenue figures provide insight into the company's sales performance and overall market demand for its products.

$1.5B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+7.95%

Avg Stock Reaction

-3.38%

Last Quarter Recap

In Q4 2025, Organon reported an EPS of $0.63, missing expectations of $0.70, which led to an 8.19% drop in stock price the following day. The company did not provide revenue figures for that quarter.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Organon to report an EPS of $0.85 and revenue of $1.5 billion for Q1 2026, reflecting cautious optimism following recent earnings trends.

Bull Case

If Organon beats EPS expectations, it could signal a strong recovery and renewed investor confidence, potentially driving the stock higher.

Bear Case

A miss on EPS or revenue could raise concerns about the company's growth trajectory and lead to further declines in stock price.

Key Metrics to Watch

EPS

$0.85

Earnings per share is a key indicator of profitability, and investors will be looking for a solid performance compared to expectations.

Revenue

$1.5B

Revenue figures provide insight into the company's sales performance and overall market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Organon achieve an EPS of at least $0.85?

This figure is crucial for assessing the company's profitability and could significantly influence investor sentiment.

What revenue figures will Organon report, and how do they compare to the $1.5 billion consensus?

Revenue performance is key to understanding market demand and the company's growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for a strong recovery in EPS, given recent trends in women's health products that could drive sales.

Supporting Evidence

Organon has a history of beating EPS estimates, with an 88% success rate over the last eight quarters.

The options market is pricing a smaller move than historical averages, suggesting that investors may be overly cautious.

Recent trends in the pharmaceutical sector indicate increasing demand for women's health products, which could positively impact revenue.

Key Risk

If the company reports an EPS significantly above $0.85, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing recent earnings performance against expectations for growth, making this quarter critical for future outlook.

Bull Confirmed If

An EPS of $0.90 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.77 would indicate ongoing challenges and could lead to a negative market reaction.

Pre-Earnings Positioning

Options Market

Implied Move

±3.19%

Historical Avg

±10.8%

Pricing cheap

The options market is pricing a relatively modest move around the earnings report, suggesting that investors are uncertain about significant changes.

Options are pricing ±3.2% while OGN has averaged ±10.8% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.1%

30d HV

129.9%

Calls (4.1M)P/C Ratio: 0.05Puts (838K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Organon beats expectations, history suggests the stock could rise by around 2% on the first day, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may see minimal movement as investors assess management's commentary.

Miss

A miss could lead to a decline of about 8% based on historical patterns, raising concerns about the company's growth trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in women's health.
2Insights into market demand and sales trends for key products.
3Management's outlook on future growth and potential challenges.
4Details on cost management and operational efficiency improvements.